Finanza

Elenchi
Perché WUXI06 è in calo 3,42%?
Approfondisci
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,65 ฿
-3,42%
(-0,20) 1G
12 ott, 16:40:00 GMT+7  ·   THB
Tutti i simboli
SimboloPrezzoCambio% di cambio
Generazione degli insight principali per WUXI06 in corso…
Apertura
5,70 ฿
Massimo
5,75 ฿
Minimo
5,65 ฿
Cap. mercato
216,75 Mld
Vol. medio
104,18K
Volume
26,14K
Max 52 sett.
6,25 ฿
Min 52 sett.
3,02 ฿
Azioni in circolazione
4,12 Mld
N. di dipendenti
15K
Apertura
5,70 ฿
Massimo
5,75 ฿
Minimo
5,65 ฿
Cap. mercato
216,75 Mld
Vol. medio
104,18K
Volume
26,14K
Max 52 sett.
6,25 ฿
Min 52 sett.
3,02 ฿
Azioni in circolazione
4,12 Mld
N. di dipendenti
15K
Articoli giornalistici
Da fonti web e partner giornalistici
Profilo
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Informazioni su Wuxi Biologics (Cayman) Inc. KKPS DR
CEOZhisheng Chen
Dipendenti14,7K
Data di fondazione2010
Sede-
Settore-
Report precedentiTutti i valori in CNY
Loading Previous Earnings...
Fatturato
Risultato netto
Tutti i valori in CNY
set 2025
dic 2025
mar 2026
giu 2026
Fatturato
5,92 Mld
5,92 Mld
5,89 Mld
5,89 Mld
Costo dei beni venduti
3,04 Mld
3,04 Mld
3,17 Mld
3,17 Mld
Costo del venduto
3,04 Mld
3,04 Mld
3,17 Mld
3,17 Mld
Spese di ricerca e sviluppo
254,93 Mln
254,93 Mln
215,11 Mln
215,11 Mln
Spese totali per ricerca e sviluppo
-
-
-
-
Spese di vendita, generali e amministrative
631,03 Mln
631,03 Mln
591,61 Mln
591,61 Mln
Spese operative
921,71 Mln
921,71 Mln
860,09 Mln
860,09 Mln
Spese operative totali
3,96 Mld
3,96 Mld
4,03 Mld
4,03 Mld
Reddito operativo
1,96 Mld
1,96 Mld
1,86 Mld
1,86 Mld
Altri redditi non operativi
33,58 Mln
33,58 Mln
42,20 Mln
42,20 Mln
EBT inclusi elementi straordinari
1,96 Mld
1,96 Mld
1,71 Mld
1,71 Mld
EBT esclusi elementi straordinari
1,94 Mld
1,94 Mld
1,70 Mld
1,70 Mld
Spese per imposte sul reddito
476,10 Mln
476,10 Mln
251,54 Mln
251,54 Mln
Aliquota fiscale effettiva
24,24%
24,24%
14,71%
14,71%
Altre spese operative
-
-
-
-
Risultato netto
1,28 Mld
1,28 Mld
1,22 Mld
1,22 Mld
Margine di profitto netto
21,70%
21,70%
20,70%
20,70%
Utili per azione
-
-
-
-
Interessi e reddito da investimento
115,29 Mln
115,29 Mln
106,38 Mln
106,38 Mln
Interesse passivo
-29,76 Mln
-29,76 Mln
-22,28 Mln
-22,28 Mln
Interessi passivi netti
85,53 Mln
85,53 Mln
84,10 Mln
84,10 Mln
Addebiti per ammortamento e svalutazione
-
-
-
-
EBITDA
2,24 Mld
2,24 Mld
2,27 Mld
2,27 Mld
Utile o perdita derivante dalla vendita di asset
317,34 Mln
317,34 Mln
-
-
I contenuti creati con l'AI potrebbero contenere errori. Scopri di più
App Google